Donald R VanDevanter (Donald R Van Devanter)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2021
Publications (10 Years): 7

Top Topics

Cystic Fibrosis

Pseudomonas Aeruginosa

Top Venues

Annals of the American Thoracic Society

Pediatric pulmonology

Future microbiology

This page only lists publications with an associated author ORCID identifier.

Publications

Michael W Konstan, David J Pasta, Donald R VanDevanter, Jeffrey S Wagener, Wayne J Morgan, null null
Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. Pediatric pulmonology 56 (5) (2021)
J Stuart Elborn, Patrick A Flume, Donald R VanDevanter, Claudio Procaccianti
Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. Future microbiology 16 (2021)
Michael W Konstan, Donald R VanDevanter, Gregory S Sawicki, David J Pasta, Aimee J Foreman, Evgueni A Neiman, Wayne J Morgan
Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. Annals of the American Thoracic Society 15 (4) (2019)
Jeffrey S Wagener, Donald R VanDevanter, Michael W Konstan, David J Pasta, Stefanie J Millar, Wayne J Morgan
Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Pediatric pulmonology 55 (3) (2019)
Wayne J Morgan, Jeffrey S Wagener, David J Pasta, Stefanie J Millar, Donald R VanDevanter, Michael W Konstan, null null
Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis. Annals of the American Thoracic Society 14 (6) (2018)
Donald R VanDevanter, Marcia L Craib, David J Pasta, Stefanie J Millar, Wayne J Morgan, Michael W Konstan, null null
Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. Pediatric pulmonology 53 (1) (2017)
Donald R VanDevanter, Sonya L Heltshe, John J LiPuma
Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies. Annals of the American Thoracic Society 13 (11) (2017)